Dr. Laura M. Spring, MD

Dr. Spring practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Spring's NPI, 1811282957, was assigned on June 16, 2011. Dr. Spring graduated from University of Massachusetts Medical School in 2011. Dr. Spring holds Massachusetts license 256404.

Dr. Spring's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Spring's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Spring is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Hospital. Dmand AI also links Dr. Spring to 3 more hospitals, 3 medical groups and 1 community health center, each named with a free account. Dr. Spring's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Spring practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Spring's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Spring is licensed in Massachusetts.

CMS data shows 995 Medicare services from Dr. Spring across 6 procedure codes in 2024, for 333 Medicare patients. Medicare paid $72,943 for them.

CMS counts 333 Medicare patients who saw Dr. Spring in 2024. The largest group is 65 to 74, with 166 patients. 75% of them have cancer, and 67% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.46, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Spring's median patient age at 71, with 95% women.

In 2024, Dr. Spring wrote 309 Medicare Part D claims for 106 patients. 82% of them were for generic drugs. CMS names the drug for 214 of them, across 7 drugs with 11 or more claims each, at $348,492 in total drug cost. In 2023, CMS named 206 claims across 5 drugs.

Dr. Spring accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Spring as offering telehealth.

Dmand AI links 93 papers to Dr. Spring, published from 2014 to 2025. 2021 was the busiest year, with 14. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Antibodies, Monoclonal, Humanized. Dr. Spring has published most often in Clin Cancer Res. Dr. Spring's most frequent co-authors are Aditya Bardia, MD, Steven Jay Isakoff, MD, PhD and Leif William Ellisen, MD, PhD.

Dmand AI links Dr. Spring to 4 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms and Breast Diseases. Dana-Farber Cancer Institute sponsors the most, 2. Open Payments lists research payments to Dr. Spring that name 1 trial.

CMS Open Payments shows 119 general payments to Dr. Spring from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. Novartis Pharmaceuticals Corporation paid the most, $30,889. It also lists 14 research payments totaling $32,377 from 2022 to 2025, naming 1 clinical trial.

Dr. Spring graduated from University of Massachusetts Medical School in 2011.